Annoroad Gene Technology Completes RMB 700 Million Financing Round and Files for Hong Kong IPO

VCBeat (WeChat ID: vcbeat) has learned that on November 2, 2017, Annoroad Gene Technology announced the completion of its latest round of financing, raising nearly RMB 700 million. This round was co-led by Shenzhen GTJA Capital Group and Ping An Ventures, with other investors including SoftBank China Capital and SAIF Partners China.

Since its inception, Annoroad has been committed to its mission of organizing and leveraging genomic information and technologies to enhance the value of life, thereby enabling gene technology to deliver increasingly profound social benefits, serve humanity, and accelerate discoveries in life sciences. The completion of this financing round will inject new momentum into the company’s development. Annoroad will continue to pursue sustainable and steady growth by adhering to a platform-based strategy centered on genomic technologies.

The funds raised in Annoroad’s latest financing round will be used to support the company’s global expansion, talent system development, R&D investment in technology, and industrial investments.

Annuoda, headquartered in Beijing, is a leading Chinese company centered on gene technology.Bio-ITEnterprise, Asia’s leading genomics center, successively recognized as one of the first batch of demonstration centers for gene testing technology applications by the National Development and Reform Commission, a national high-tech enterprise, and part of Beijing’s Bio-pharmaceutical Industry Leapfrog Development Project (G20Engineering) Enterprises, China's Most Investment-Worthy Enterprises,2016Honors and qualifications such as “China’s Most Technologically Leading Enterprise,” and it operates a Postdoctoral Research Station.

The company focuses on the industrial application of genomics-centric technologies in human medical health and life science research. Its current business covers the following major areas: